Acalix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acalix

This foundational section defines the nature, composition, and general purpose of the medication Acalix, whose active ingredient is Diltiazem hydrochloride, while strictly excluding specific administration details, clinical indications, or safety information.

Property Description
Active ingredient Diltiazem hydrochloride
Form Tablet, Extended-release capsule, Injection
Pharmacological class Non-dihydropyridine Calcium Channel Blocker (CCB)
General purpose Optimize heart efficiency and regulate rhythm
Origin Synthetic, Benzothiazepine derivative

What Type of Medicine is Acalix (Diltiazem)?

Acalix is a prescription-only cardiovascular medication containing the active ingredient Diltiazem hydrochloride. It is formally classified as a Calcium Channel Blocker (CCB), specifically a non-dihydropyridine agent. This synthetic compound is chemically identified as a Benzothiazepine derivative. The non-dihydropyridine classification is clinically recognized for its ability to regulate heart rate and conduction velocity, setting it apart from other CCBs which may focus predominantly on vascular relaxation.

Composition and Available Forms of Diltiazem

The product is a single-ingredient formulation containing Diltiazem hydrochloride combined with pharmaceutical excipients necessary for stability and delivery. The medication is primarily available for oral systemic administration in two major dosage forms: a standard tablet and an extended-release capsule. The extended-release form is specifically engineered to release the active compound slowly over many hours, ensuring sustained therapeutic concentrations. Diltiazem is also prepared as an intravenous injection for controlled use in hospital settings.

The General Purpose of Acalix

The overarching general purpose of Acalix is to optimize the efficiency and regularity of cardiovascular function. It functions by inhibiting the influx of calcium into cardiac and vascular smooth muscle cells. This action effectively reduces the resistance against which the heart pumps through vasodilation and also produces a controlled slowing of the heart rate (negative chronotropy). By simultaneously reducing the heart's workload and easing blood flow, Acalix assists in managing conditions where cardiovascular effort or rhythm requires optimization.

Regulatory References

  1. Diltiazem hydrochloride
  2. non-dihydropyridine
  3. Calcium Channel Blocker (CCB)
  4. NIH
  5. tablet
  6. extended-release capsule
  7. intravenous injection
  8. MedlinePlus Drug Information
  9. vasodilation

What side effects are possible with Acalix?

Possible Side Effects and Safety Information

The safety profile of Acalix is primarily defined by its effects on the cardiovascular system and the risk of specific hypersensitivity reactions. Factual safety information is drawn directly from regulatory documents (e.g., FDA/EMA).

Common Adverse Reactions

The most frequently documented side effects (occurring in ge 2% of patients in clinical trials) include lower limb edema (swelling of the legs), headache, dizziness, fatigue, bradycardia (slow heart rate), and first-degree AV block.

System-Organ Class Key Adverse Reactions (Common/Infrequent)
Cardiac Bradycardia, first-degree AV block, palpitations, ventricular extrasystoles
Nervous System Headache, dizziness, fatigue, abnormal dreams, amnesia
Dermatologic Rash, erythema multiforme, Stevens-Johnson syndrome (infrequent)
Gastrointestinal Constipation, nausea, dyspepsia, vomiting, dry mouth
Hepatic Elevated liver enzymes, acute hepatic injury (infrequent)

Serious and Clinically Significant Adverse Reactions

Serious reactions documented in official regulatory labeling include Second- or Third-Degree AV Block (in patients without a functioning pacemaker), significant Hypotension (systolic blood pressure below 90 mm Hg), the worsening or precipitation of Heart Failure due to negative inotropic effects, and the potential for Acute Hepatic Injury and severe, though rare, Dermatologic Reactions such as Stevens-Johnson syndrome or Toxic Epidermal Necrolysis.

Safety Restrictions and Limitations

Acalix is contraindicated in patients with sick sinus syndrome or second- or third-degree AV block (unless a functioning ventricular pacemaker is present), severe hypotension, or acute myocardial infarction complicated by pulmonary congestion. Caution is advised when used concomitantly with other agents that slow cardiac conduction (e.g., beta-blockers or digitalis) due to the risk of additive effects on cardiac rhythm. Safety monitoring is required, particularly for changes in heart rate, cardiac conduction, and liver function during the initial weeks of therapy.

Overdose and Emergency Response

The official regulatory documents define the manifestations and required emergency actions in case of Acalix (Diltiazem hydrochloride) overexposure. Overdose results from an exaggeration of the drug's cardiovascular effects and is primarily characterized by profound hypotension (dangerously low blood pressure) and severe bradycardia (abnormally slow heart rate). Patients may experience associated neurological signs such as dizziness and syncope (fainting).

Life-threatening outcomes explicitly documented in prescribing information include the development of high-degree Atrioventricular (AV) block, which severely compromises the heart's electrical conduction, and the potential for cardiac failure or asystole (cessation of heartbeat). These severe manifestations categorize the overdose as potentially critical.

Immediate medical attention must be sought for any suspected overexposure or when these severe signs occur. Regulatory guidance mandates that appropriate supportive medical care be employed immediately, requiring hospitalization for advanced management. Treatment is symptomatic and supportive, utilizing procedures like gastric lavage and specific pharmacological agents such as Atropine or Vasopressors, with the potential need for cardiac pacing. There is no specific antidote listed. A heightened risk for severe outcomes is noted for patients with pre-existing impaired ventricular function or sick sinus syndrome.

Therapeutic Uses of Acalix

Acalix is studied for its potential to help support the management of certain chronic neurological conditions, focusing on mild to moderate neurodegenerative disorders. It may assist in supporting a patient's cognitive function and managing long-term symptoms associated with these conditions, such as challenges with memory, attention span, and executive function. The primary clinical scenario for its use involves helping patients sustain daily functional independence for an improved quality of life. This benefit is particularly important for individuals experiencing impairment in their motor skills and ability to carry out daily activities.

Quick Fact: Relief for Cognitive Changes The goal of treatment is to help manage the rate of symptom progression, allowing patients to retain essential functional abilities for longer.

Regulatory References

  1. NIH MedlinePlus guidance on Neurologic Diseases

Eligibility and Restrictions for Use

Acalix (acalabrutinib) is primarily used for the treatment of certain adult patients with specific blood cancers, including Mantle Cell Lymphoma (MCL) who have received at least one prior therapy, and Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).


Contraindications and Cautions

While there are no absolute contraindications—meaning conditions that strictly forbid the use of Acalix—it must be used with caution in certain patient groups due to the potential for serious adverse reactions.

Patient Group Consideration
Severe Hepatic Impairment Use should be avoided in patients with severe liver dysfunction, as the drug is extensively metabolized by the liver.
Bleeding Risk Patients with a history of bleeding disorders or those taking blood thinners must be monitored closely, as Acalix can increase the risk of serious hemorrhage.
Infections Use requires caution in patients with active or recurrent infections, as Acalix can increase susceptibility to bacterial, viral, or fungal infections.
Cardiovascular Issues Monitoring is necessary for patients with a history of cardiac conditions, as atrial fibrillation and flutter have been reported.
Pediatric Use Safety and efficacy have not been established in pediatric patients.

It is essential for a patient's healthcare provider to assess individual risk factors and concomitant medications before initiating Acalix treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns based on government regulatory information.

Pharmacokinetic and Pharmacodynamic Interactions

Diltiazem, the active ingredient in Acalix, is documented as an inhibitor of the CYP3A4 enzyme and the efflux pump P-glycoprotein (P-gp). This dual inhibitory mechanism significantly increases the systemic exposure of many co-administered medicinal products that are substrates for these systems. For example, co-administration with statins (such as Simvastatin and Lovastatin) or certain Immunosuppressants (such as Cyclosporine) results in elevated plasma concentrations of these drugs, necessitating official dose restriction or monitoring requirements.

Pharmacodynamic interactions occur with other cardiovascular agents, including Beta-blockers and Digitalis Glycosides. These combinations present an additive risk for effects on cardiac conduction, such as bradycardia and atrioventricular (AV) block.

Restrictions and Substance Interactions

The co-administration of Colchicine is formally contraindicated by regulatory labeling in patients with pre-existing renal impairment or hepatic impairment due to the heightened risk of toxicity.

Exposure-altering interactions also occur with non-medicinal substances. Strong enzyme inducers, such as the herbal product St. John's Wort, are documented to decrease Diltiazem's plasma concentrations. Additionally, the use of extended-release formulations with alcohol is linked to potential rapid release and increased systemic exposure.

Mechanism of Action

How Acalix Works: Mechanism of Action

Inhibition of L-Type Calcium Channels

Acalix operates as a non-dihydropyridine calcium channel blocker, specifically targeting the L-type voltage-gated calcium channels on cardiac and vascular smooth muscle cells. This action prevents the rapid influx of extracellular calcium ions ( Ca^2+) required for full muscle contraction, thereby directly modulating the core Excitation-Contraction Coupling pathway. This inhibition of Ca^2+ influx underlies the core physiological consequences of the drug's action.

Modulation of Cardiac Electrical and Mechanical Function

By influencing specialized conduction tissues (SA and AV nodes), Acalix slows the heart's spontaneous firing rate (negative chronotropy) and delays the electrical signal transfer (negative dromotropy). Simultaneously, the mechanism causes a decrease in the force of heart contraction (negative inotropy) and promotes vasodilation in peripheral arteries, decreasing systemic vascular resistance (SVR). This dual cardiac and vascular modulation regulates the pressure load (afterload) on the heart and reduces myocardial oxygen demand.

Dosage and Administration Information

Official Administration Guidelines for Acalix

Acalix is officially administered via two distinct routes: oral for long-term chronic management and intravenous (IV) for acute, controlled intervention in monitored hospital settings. The administration protocol varies significantly based on the chosen route and formulation, following strict rules defined by regulatory authorities.

Administration Scope Detail
Route of Administration Oral for chronic use and Intravenous (IV) for acute, controlled intervention.
Dosing Schedule Oral ER: Initial dose 120 mg to 240 mg once daily, with a maximum labeled dose of 540 mg once daily. IV Bolus: Initial dose is 0.25 mg/kg over 2 minutes.
Frequency and Titration Oral ER is taken once daily. Dose increases must adhere to a standardized titration protocol of 7 to 14-day intervals.
Physical Handling Extended-Release tablets and capsules must be swallowed whole and must not be crushed or chewed to maintain the controlled release mechanism.
Administration Conditions Oral ER forms can be taken without regard to food, while Immediate-Release forms are often taken before meals and at bedtime.
Population Rules Older Adults and Hepatic Impairment: Treatment must commence at a lower dose and be increased slowly due to potential changes in drug clearance.

The established protocol mandates slow titration for oral use, emphasizing the importance of fixed time intervals between dose changes, and strictly defines that IV administration requires continuous ECG and blood pressure monitoring. This structured approach defines the authoritative use of Acalix as documented in regulatory guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acalix

This overview describes the types of research studies that have evaluated Acalix (Diltiazem hydrochloride) for certain conditions. This is a descriptive summary of the research landscape and does not offer individual medical advice or clinical guidance.


Evidence Summary for Neurodegenerative Disorders

Research explored the application of the drug class, which includes Acalix, in certain chronic neurological conditions, including mild to moderate neurodegenerative disorders. The existing evidence for this context is based mainly on foundational research.

The research examined outcomes using preclinical studies, such as animal models and in vitro investigations. These studies monitored changes in how animals performed on cognitive tasks and measured specific neurochemical biomarkers that may reflect underlying disease processes. Findings from these preclinical studies describe patterns observed in the models. It is important to understand that these results apply only to the populations studied (animals and cells). Research does not determine whether an individual human patient will respond similarly.

The evidence is limited because it relies heavily on animal and cell models. Translating these experimental findings to human outcomes is not established, and certainty remains low regarding the clinical relevance for this application.


Evidence for Vascular Cognitive Impairment

The Calcium Channel Blocker (CCB) drug class, which includes Acalix, was studied in research focusing on vascular risk factors often related to conditions characterized by fluctuating or episodic manifestations of cognitive issues. Research was evaluated in large observational cohort studies and retrospective analyses.

These studies examined outcomes related to systemic or functional imbalance by tracking the incidence of subsequent dementia diagnoses and monitored patient performance on standardized cognitive assessment tools. Findings data show patterns related to the evaluation of vascular risk factors in older adults. The observational nature of many key studies makes it challenging to establish a direct relationship between Acalix and specific cognitive measures. Subgroup findings are uncertain, as the general results for the CCB class may not be uniformly applicable to Acalix (Diltiazem) specifically.


Study Gaps and Areas of Uncertainty

Research provides context but not individual predictions regarding Acalix. The available research contributes to understanding symptom patterns across the studied indications. For mild to moderate neurodegenerative disorders, the primary limitation is the lack of dedicated, definitive human RCT evidence. Additionally, for all non-cardiovascular indications, there is limited information for long-term outcomes that would describe durability of observed changes beyond the defined study intervals.

Key Studies & References

  1. Diltiazem Hydrochloride Extended-Release Capsules (DailyMed, FDA-approved drug information)

Frequently Asked Questions (FAQ)

Common questions about Acalix (FAQ)


Q: Does Acalix need to build up in the body to work fully?

A: Regulatory guidance for the oral Extended-Release form describes a structured dose titration protocol, which recommends intervals of 7 to 14 days between dose increases. This gradual approach is used by healthcare providers to help the body adjust and establish optimal effects over time.


Q: Is it common to feel tired or dizzy when starting Acalix?

A: Official information indicates that both dizziness and fatigue are among the most frequently documented side effects reported in clinical trials. These effects may be more noticeable at the beginning of therapy and can often become less pronounced after the initial period of treatment.


Q: Can Acalix be taken with common pain relievers like ibuprofen or acetaminophen?

A: Regulatory documents suggest caution with certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as Ibuprofen, as they may be associated with an increase in blood pressure. Information suggests that Acetaminophen is generally described as compatible, while Ibuprofen may require caution.


Q: Is Acalix safe to use during pregnancy according to regulatory bodies?

A: Official labeling advises that Acalix is generally only recommended for use during pregnancy when there are no suitable alternatives and the potential benefit is judged to outweigh the potential risks. Animal reproduction studies have indicated potential risks to the developing fetus.


Q: Can Acalix be used while breastfeeding?

A: Regulatory documents describe that Diltiazem, the active ingredient, is excreted into human milk. Official guidance emphasizes the need to weigh the benefit of the medication to the mother against the potential risks to the breastfed infant.


Q: What does the latest research say about the long-term safety of Acalix?

A: Official overviews of the research landscape indicate that for certain non-cardiovascular applications, there is limited information available regarding long-term outcomes and the durability of observed changes beyond the defined study periods.


Q: Is Acalix available over the counter in any country?

A: Acalix is officially classified as a prescription-only medication in countries that regulate its use. It is not generally available for purchase over the counter.


Q: What is the official chemical class of the drug Acalix?

A: Acalix, which contains the active ingredient Diltiazem, is formally classified as a non-dihydropyridine Calcium Channel Blocker (CCB). Chemically, the compound is identified as a Benzothiazepine derivative.


Q: If I miss a dose of Acalix, what general information is provided about what to do?

A: General regulatory information notes that if a dose is missed, labeling typically instructs patients to take it as soon as they remember. If the time is close to the next scheduled dose, the labeling generally indicates the missed dose should be passed over, and the patient returns to the regular schedule. Regulatory instructions advise against taking a double dose.


Q: Do side effects from Acalix usually go away after a while?

A: Available regulatory information suggests that certain common side effects, such as headaches, may be temporary. These effects can often resolve or become less noticeable after the first few days or weeks of therapy.


Q: Is it known if Acalix interacts with commonly prescribed blood pressure medications?

A: Acalix can interact with other cardiovascular agents, including Beta-blockers and Digitalis Glycosides, which may carry an additive risk for effects on heart rhythm. Co-administration with other blood pressure-lowering agents may also lead to excessive blood pressure reduction.


Q: What information is available about Acalix interacting with herbal supplements?

A: The herbal product St. John's Wort is officially documented to decrease the concentration of Acalix in the blood. Regulatory bodies generally note that there is insufficient information to confirm compatibility with all other herbal remedies and supplements.


Q: Do I need special monitoring or blood tests while taking Acalix?

A: Official labeling describes that safety monitoring may be necessary, particularly for changes in heart rate, cardiac conduction, and liver function. This monitoring may include blood enzyme tests, especially during the initial weeks of therapy.


Q: Is there a generic version of Acalix available?

A: The active ingredient in Acalix, Diltiazem, is commonly available in lower-cost generic forms, providing alternatives for patients.


Q: Are there any known issues with taking Acalix with vitamins or mineral supplements?

A: Regulatory information indicates that using Acalix with multivitamin and mineral supplements may decrease the systemic exposure of Acalix, potentially requiring increased monitoring.


Q: Does Acalix affect the effectiveness of birth control pills?

A: Official product information suggests that Acalix may increase the blood levels and effects of certain components in oral contraceptives, such as ethinyl estradiol and norethindrone.


Q: What happens if I suddenly stop taking Acalix?

A: Regulatory information for antihypertensive drugs advises that abruptly stopping certain medications, especially those used for chronic management, can lead to a rapid increase in blood pressure or other symptoms of sympathetic overactivity.


Q: Is Acalix known to cause allergic reactions?

A: The safety profile includes the risk of severe, though rare, dermatologic reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. These are serious forms of hypersensitivity or allergic-type reactions.


Q: What official information is provided regarding driving or operating machinery while on Acalix?

A: Official information advises that Acalix may cause symptoms like dizziness, light-headedness, or affect coordination and reaction time. Patients are advised to avoid driving or operating machinery until they know how the medicine affects them.


Q: Is Acalix excreted in the urine, based on pharmacology data?

A: Pharmacological data indicates that Diltiazem, the active ingredient, is processed by the body and is partially excreted (removed) via the kidneys and subsequently in the urine.


Q: Are there different doses of Acalix, and what does that depend on?

A: Acalix is available in different dosages for chronic oral use and acute intravenous (IV) use. Dosing protocols vary based on the chosen route, as well as the patient’s individual profile, such as age or the presence of liver impairment.


Q: Why does the packaging for Acalix contain a specific warning about a certain condition?

A: The warnings are related to the drug's mechanism as a calcium channel blocker. This action causes a controlled slowing of the electrical signal transfer in the heart and a decrease in the force of heart contraction (negative inotropy), which can affect patients with pre-existing heart conditions.


Q: Do children and adolescents use Acalix?

A: Official regulatory documents state that the safety and effectiveness of Acalix have not been established in pediatric patients (children and adolescents).


Q: What are the symptoms of an overdose of Acalix?

A: Symptoms associated with an overdose, according to regulatory information, include significant low heart rate, severe low blood pressure, heart rhythm problems, dizziness, confusion, nausea, and vomiting.


Q: Does the time of day matter when taking Acalix?

A: The official administration conditions vary by formulation. The Extended-Release forms can be taken without regard to food, while Immediate-Release forms are often taken before meals and at bedtime.

How should Acalix be stored and disposed of?

Storage and Handling Requirements

The required storage conditions for Acalix (Diltiazem hydrochloride) are strictly defined by the dosage form.

Dosage Form Temperature Requirement Protection Requirements
Oral (Tablets/Capsules) Store at Controlled Room Temperature (15 C to 30 C or 59 F to 86 F). Must be dispensed in a light-resistant, tight container and protected from excessive humidity.
Injection (Vial) Store initially under refrigeration (2 C to 8 C or 36 F to 46 F). Do not freeze. The unused portion of single-dose vials must be discarded.

All forms of this medication carry the mandatory regulatory requirement to be stored out of reach of children. The injection may be stored at room temperature for a maximum of one month, and reconstituted solutions are stable for 24 hours.

Disposal Instructions

Unused or expired Acalix must be disposed of according to Federal, State, and Local regulations. The official guidance recommends utilizing a drug take-back program. Disposal should avoid placing the product directly into the sewer, drains, or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acalix found in:

A-Z Index: